QIAGEN has expanded its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.  These new solutions join the growing portfolio of cell and gene therapy dPCR assays for the biopharma market, including residual DNA quantification kits for commonly used productio...